premiumShareholders Approve Kimia Farma's Rights Issue Plan

Shareholders Approve Kimia Farma's Rights Issue Plan

The Extraordinary General Meeting of Shareholders (EGMS) of PT Kimia Farma Tbk (KAEF) approved the plan to issue new shares to increase capital with Pre-emptive Rights for a maximum of 2,779,397,000 series B shares with a nominal value of Rp 100 per share through the mechanism of Limited Public Offering.

premiumKimia Farma Reduces Price of PCR Tests

Kimia Farma Reduces Price of PCR Tests

PT Kimia Farma Tbk (KAEF) is ready to implement the Ministry of Health's decision to reduce the rate/price of polymerase chain reaction (PCR) tests based on the Circular of the Director-General Health Services No. HK.02.02/I/2824/2021 concerning the Highest Tariff Limit for Reserve Transcription Polymerase Chain Reaction (RT-PCR) examination, effective from Tuesday, August 17, 2021.